Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gabriel Smith

Neurological Surgery Cleveland, OH Medical Doctor

NPI 1598056269 CMS profile 1391065

11100 Euclid Ave, Cleveland, OH 44106

Open in the dashboard

General payments

$72,120

255 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gabriel Smith of Cleveland, OH is reported in the CMS Open Payments database as having received $72,120 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,374 50
2024 General $5,157 31
2023 General $17,860 68
2022 General $8,033 48
2021 General $9,628 40
2020 General $14,047 17
2019 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gabriel Smith
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Gabriel Smith were reported at $17,374. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Gabriel Smith Neurological Surgery median Middle half National median
2019 $20 $582 $138–$3,006 $163
2020 $14,047 $294 $76–$2,174 $114
2021 $9,628 $387 $105–$2,432 $132
2022 $8,033 $542 $139–$2,989 $149
2023 $17,860 $534 $145–$2,697 $160
2024 $5,157 $574 $155–$3,046 $164
2025 $17,374 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $19,199 98 payments
  2. Stryker Corporation $18,426 30 payments
  3. Medtronic, Inc. $17,183 62 payments
  4. Globus Medical, Inc. $15,889 46 payments
  5. Arthrex, Inc. $501 8 payments
  6. Nexus Medical Technologies LLC $296 2 payments
  7. Arteriocyte Medical Systems, Inc. $261 1 payment
  8. SI-BONE, Inc. $224 2 payments
  9. Centinel Spine, LLC $56 2 payments
  10. Medtronic USA, Inc. $43 2 payments
  11. Other $42 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,300 20 payments
  2. Food and Beverage $10,669 206 payments
  3. Travel and Lodging $7,467 26 payments
  4. Education $3,409 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,275 1 payment
Products named General payments · program years 2019–2025
  1. TRITANIUM $10,324 9 payments
  2. XLIF $10,024 47 payments
  3. EXCELSIUS GPS $8,947 13 payments
  4. ARIA $8,750 1 payment
  5. EVEREST XT $8,750 1 payment
  6. CASCADIA $8,750 1 payment
  7. ES2 $8,750 1 payment
  8. MIDAS REX $8,491 3 payments
  9. TLIF $5,205 24 payments
  10. CAPRI CORPECTOMY CAGE SYSTEM $3,931 4 payments
  11. Other $25,625 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

94

Median for Neurosurgery: 83

Drug cost

$1,045

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 35 $542
Pregabalin Generic 11 $325
Oxycodone Hcl Generic 13 $69
Cyclobenzaprine Hcl Generic 11 $45
Methylprednisolone Generic 12 $43
Tramadol Hcl Generic 12 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$281,894

Medicare's payments for the services billed

Medicare patients

267

Average age 73

Services billed

910

132 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Diabetes 37%
Ischemic heart disease 37%
Chronic kidney disease 29%
Osteoporosis 24%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record